Sven Mahner

TL;DR: Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer amongThose receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity.

TL;DR: The recommendations presented here are based on the best available evidence and expert agreement and are presented with a summary of evidence supporting each recommendation.

TL;DR: Progression-free survival was significantly longer in the olaparib plus chemotherapy group than in the chemotherapy alone group and the BRCA mutation status was known for 107 patients (either at baseline or determined retrospectively), and prespecified exploratory analyses included efficacy by BRCa mutation status, assessed retrospectively.

TL;DR: Systematic pelvic and paraaortic lymphadenectomy in patients with advanced ovarian cancer who had undergone intraabdominal macroscopically complete resection and had normal lymph nodes both before and during surgery was not associated with longer overall or progression‐free survival and was associated with a higher incidence of postoperative complications.

TL;DR: This score is the first prospectively validated instrument to positively predict surgical outcome in recurrent ovarian cancer and will be enrolled in the recently started randomized prospective DESKTOP III trial investigating the role of surgery in recurrent platinum-sensitive ovarian cancer.